Answers are grounded in this paper and cite their sources.
Introduction The cost-effectiveness of adding bevacizumab biosimilar with or without chemotherapy (CT) and drug wastage in treating platinum-resistant recurrent ovarian cancer (PRrOC) was assessed.
No takes yet. Share an insight, caveat, or question.
Lai et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: